Collegeville, PA, United States of America

Charles William Blackledge, Jr


 

Average Co-Inventor Count = 10.8

ph-index = 2

Forward Citations = 34(Granted Patents)


Company Filing History:


Years Active: 2014-2017

Loading Chart...
Loading Chart...
3 patents (USPTO):

Title: The Innovations of Charles William Blackledge, Jr.

Introduction

Charles William Blackledge, Jr. is an accomplished inventor based in Collegeville, PA (US). He holds a total of 3 patents that contribute significantly to the field of pharmaceutical research. His work primarily focuses on inhibitors of Enhancer of Zeste Homolog 2 (EZH2), which have implications in cancer treatment.

Latest Patents

Blackledge's latest patents include innovative compounds that serve as inhibitors of EZH2. The first patent describes novel compounds according to Formula (III)(a) that are designed to inhibit EZH2, along with pharmaceutical compositions containing these compounds. The second patent also focuses on EZH2 inhibitors, detailing novel compounds according to Formula (I), their preparation processes, and their therapeutic applications for cancer treatment.

Career Highlights

Throughout his career, Blackledge has worked with notable organizations, including GlaxoSmithKline Intellectual Property (No. 2) Limited and GlaxoSmithKline LLC. His contributions to these companies have been instrumental in advancing research and development in the pharmaceutical sector.

Collaborations

Some of his notable coworkers include William Henry Miller and Stuart Paul Romeril. Their collaborative efforts have further enriched the research environment in which Blackledge operates.

Conclusion

Charles William Blackledge, Jr. exemplifies the spirit of innovation in the pharmaceutical industry through his significant contributions and patents. His work on EZH2 inhibitors showcases the potential for advancements in cancer therapy.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…